In a finding that could lead to development of new patient-specific strategies for improving diagnosis and treatment of Alzheimer's disease, a new study published in the journal Cell reveals that patients with different clinical histories and degrees of brain damage have distinct molecular structures of beta-amyloid fibrils that may predominate in their brains.
"This work represents the first detailed characterization of the molecular structures of beta-amyloid fibrils that develop in the brains of patients with Alzheimer's disease," says senior study author Robert Tycko of the National Institutes of Health. "This detailed structural model may be used to guide the development of chemical compounds that bind to these fibrils with high specificity for purposes of diagnostic imaging, as well as compounds that inhibit fibril formation for purposes of prevention or therapy."
Tycko and his team had previously noticed that beta-amyloid fibrils grown in a dish have different molecular structures, depending on the specific growth conditions. Based on this observation, they suspected that fibrils found in the brains of patients with Alzheimer's disease are also variable and that these structural variations might relate to each patient's clinical history. But it has not been possible to directly study the structures of fibrils found in patients because of their low abundance in the brain.
"This may mean that fibrils in a given patient appear first at a single site in the brain, then spread to other locations while retaining the identical molecular structure," Tycko says. "Our study also shows that certain fibril structures may be more likely than others to cause Alzheimer's disease, highlighting the importance of developing imaging agents that target specific fibril structures to improve the reliability and specificity of diagnosis."